Bong-sook Baek

Array ( [id] => 18374372 [patent_doc_number] => 20230149451 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-18 [patent_title] => PHARMACEUTICAL COMPOSITION COMPRISING OXIDIZABLE BIPHENOL AND MANGANESE PORPHYRIN, AND METHOD OF USING THE SAME [patent_app_type] => utility [patent_app_number] => 17/985504 [patent_app_country] => US [patent_app_date] => 2022-11-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8024 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17985504 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19111137 [patent_doc_number] => 20240122887 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-18 [patent_title] => THERAPEUTIC USES OF L-4-CHLOROKYNURENINE [patent_app_type] => utility [patent_app_number] => 17/958169 [patent_app_country] => US [patent_app_date] => 2022-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10247 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17958169 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18915733 [patent_doc_number] => 11877999 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-01-23 [patent_title] => Small molecule antiviral drug treatment for human papillomavirus infections [patent_app_type] => utility [patent_app_number] => 17/935408 [patent_app_country] => US [patent_app_date] => 2022-09-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 11 [patent_no_of_words] => 15928 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 124 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17935408 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18169597 [patent_doc_number] => 20230036208 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-02 [patent_title] => EXTENDED RELEASE COMPOSITIONS COMPRISING PYRIDOSTIGMINE [patent_app_type] => utility [patent_app_number] => 17/949300 [patent_app_country] => US [patent_app_date] => 2022-09-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35419 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 137 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17949300 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18244009 [patent_doc_number] => 20230076320 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-09 [patent_title] => NORFENFLURAMINE TO TREAT DRAVET SYNDROME [patent_app_type] => utility [patent_app_number] => 17/899942 [patent_app_country] => US [patent_app_date] => 2022-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23719 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17899942 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18244009 [patent_doc_number] => 20230076320 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-09 [patent_title] => NORFENFLURAMINE TO TREAT DRAVET SYNDROME [patent_app_type] => utility [patent_app_number] => 17/899942 [patent_app_country] => US [patent_app_date] => 2022-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23719 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17899942 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18107916 [patent_doc_number] => 20230000796 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-05 [patent_title] => INTRANASAL ADMINISTRATION OF KETAMINE TO CLUSTER HEADACHE PATIENTS [patent_app_type] => utility [patent_app_number] => 17/823301 [patent_app_country] => US [patent_app_date] => 2022-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6660 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17823301 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18091220 [patent_doc_number] => 20220409561 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-29 [patent_title] => METHODS OF ADMINISTERING GAMMA-HYDROXYBUTYRATE COMPOSITIONS WITH DIVALPROEX SODIUM [patent_app_type] => utility [patent_app_number] => 17/896483 [patent_app_country] => US [patent_app_date] => 2022-08-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18623 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17896483 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18282612 [patent_doc_number] => 20230098084 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-30 [patent_title] => PHARMACEUTICAL COMPOSITIONS AND ORAL DOSAGE FORMS OF KETAMINE DERIVATIVES [patent_app_type] => utility [patent_app_number] => 17/887049 [patent_app_country] => US [patent_app_date] => 2022-08-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30368 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 164 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17887049 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18178822 [patent_doc_number] => 20230039551 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-09 [patent_title] => BUFFER- AND CHELATOR-FREE, STABLE OPHTHALMOLOGICAL COMPOSITIONS OF KETOROLAC AND PHENYLEPHRINE AND APPLICATIONS THEREOF [patent_app_type] => utility [patent_app_number] => 17/871922 [patent_app_country] => US [patent_app_date] => 2022-07-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 49219 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 75 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17871922 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18323312 [patent_doc_number] => 20230121440 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-20 [patent_title] => HETEROCYCLYLAMINES AS PI3K INHIBITORS [patent_app_type] => utility [patent_app_number] => 17/866942 [patent_app_country] => US [patent_app_date] => 2022-07-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 84398 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17866942 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19496541 [patent_doc_number] => 20240335559 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-10 [patent_title] => CYCLOHEXANE LIPIDOIDS FOR NUCLEIC ACID TRANSFECTION AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/579456 [patent_app_country] => US [patent_app_date] => 2022-07-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19603 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 309 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18579456 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18107972 [patent_doc_number] => 20230000852 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-05 [patent_title] => Treatment of Dermal Cytokine Storm Syndromes [patent_app_type] => utility [patent_app_number] => 17/851165 [patent_app_country] => US [patent_app_date] => 2022-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6899 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 99 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17851165 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18018882 [patent_doc_number] => 20220370381 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-24 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING SEIZURE DISORDERS [patent_app_type] => utility [patent_app_number] => 17/843512 [patent_app_country] => US [patent_app_date] => 2022-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23780 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17843512 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17881092 [patent_doc_number] => 20220296569 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-22 [patent_title] => COMPOSITION FOR PREVENTING OR TREATING BRAIN-NERVOUS SYSTEM DISEASES COMPRISING RITA OR DERIVATIVES THEREOF [patent_app_type] => utility [patent_app_number] => 17/831879 [patent_app_country] => US [patent_app_date] => 2022-06-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4332 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17831879 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18383342 [patent_doc_number] => 11654106 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-05-23 [patent_title] => Aqueous suspension suitable for oral administration [patent_app_type] => utility [patent_app_number] => 17/824993 [patent_app_country] => US [patent_app_date] => 2022-05-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3182 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 104 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17824993 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18230823 [patent_doc_number] => 20230069817 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2023-03-02 [patent_title] => BUPROPION AS A MODULATOR OF DRUG ACTIVITY [patent_app_type] => utility [patent_app_number] => 17/748475 [patent_app_country] => US [patent_app_date] => 2022-05-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 63820 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17748475 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18230823 [patent_doc_number] => 20230069817 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2023-03-02 [patent_title] => BUPROPION AS A MODULATOR OF DRUG ACTIVITY [patent_app_type] => utility [patent_app_number] => 17/748475 [patent_app_country] => US [patent_app_date] => 2022-05-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 63820 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17748475 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19316796 [patent_doc_number] => 20240238336 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-18 [patent_title] => COPPER NANOCLUSTERS, METHODS FOR OBTAINING SAME AND THE USE THEREOF IN THE TREATMENT OF MENKES DISEASE [patent_app_type] => utility [patent_app_number] => 18/558581 [patent_app_country] => US [patent_app_date] => 2022-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8947 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18558581 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17774871 [patent_doc_number] => 20220241220 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-04 [patent_title] => BUPROPION AS A MODULATOR OF DRUG ACTIVITY [patent_app_type] => utility [patent_app_number] => 17/721827 [patent_app_country] => US [patent_app_date] => 2022-04-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 63782 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17721827 [rel_patent_id] =>[rel_patent_doc_number] =>)